Furthermore, in vivo experiments displayed that DET not only inhibited pancreatic tumor growth and metastasis but also amplified the antitumor capacity of gemcitabine, which was associated with the downregulation of NF-κB and its downstream gene products [98]. The gene discussed is NFKB1; the disease is pancreatic neoplasm.